IQVIA: The 340B Drug Pricing Program Exceeds $100B in 2022

This article is the latest in IQVIA’s series of yearly reports on the size and growth of the 340B drug discount program. In 2022, 340B sales exceeded $100B in whole acquisition cost in dollars for the first time despite contract pharmacy restrictions imposed by manufacturers. Looking ahead, 340B growth is likely to be influenced by continued developments in contract pharmacy restrictions and related court cases, the impact of the Inflation Reduction Act, recent changes in pricing strategies in the insulin market, and the expansion of the 340B patient definition.

Download this white paper on the Iqvia website here to learn more.

Scroll to Top